A Phase I Study Evaluating Combined Zevalin (Ibritumomab Tiuxetan) and Valcade (Bortezomib) in Relapsed/Refractory Low-Grade or Follicular B-Cell and Mantle Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 26 Dec 2016
At a glance
- Drugs Bortezomib; Ibritumomab tiuxetan; Rituximab
- Indications Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 22 Dec 2016 Status changed from active, no longer recruiting to completed.
- 09 Jan 2012 Actual patient number is 12 according to ClinicalTrials.gov.
- 09 Jan 2012 Actual end date (1 Oct 2011 ) added as reported by ClinicalTrials.gov.